COMUNICADO: TiGenix and Takeda Announce Alofisel® (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn's Di

Publicado 23/03/2018 19:03:41CET

References 1. Panes J, Garcia-Olmo D, Van Assche G, et al., Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomized, double-blind controlled trial. The Lancet. 2016; 388(10051): 1281-1290. 2. Data on file. 3. Panes J, Garcia-Olmo D, Van Assche G, et al., Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2017. Available at: http://www.gastrojournal.org/article/S0016-5085(17)36726-4/fulltext . Accessed February 2018.

Photo: https://mma.prnewswire.com/media/658214/Takeda_Logo.jpg https://mma.prnewswire.com/media/658215/TiGenix_Logo.jpg

CONTACT: For TiGenix: Claudia Jiménez, Senior Director, InvestorRelations and Communications, T: +34-91-804-9264,claudia.jimenez@tigenix.com; Media enquiries: Consilium StrategicCommunications, T: +44-20-3709-5700, tigenix@consilium-comms.com; ForTakeda: Kazumi Kobayashi, Media in Japan, T: +81-33-278-2095,luke.willats@takeda.com; Luke Willats, Media outside of Japan, T:+41-44-555-1145, luke.willats@takeda.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación